Dan W
Member
- Joined
- Jan 22, 2013
- Messages
- 1,528
Question-asker said:You didn't specifically recommend creatine to anyone but in your interview with John Barkhausen on Autoimmune and Movement Disorders at the beginning of the interview you said
"There are people demonstrating improvement in the degenerative diseases with very simple antioxidant supplements and creatine supplements and such"
It was a generalised statement but it got me thinking of creatine and its involvement in the energy cycle.
Does it have specific benefits or possible uses in degenerative disease
Ray Peat said:It does seem to have good effects, but I haven't had any experience with it, and it's important to know the purity of any supplement.
1. PLoS One. 2012;7(2):e30554.
Creatine protects against excitoxicity in an in vitro model of neurodegeneration.
Genius J(1), Geiger J, Bender A, Möller HJ, Klopstock T, Rujescu D.
(1)Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany.
Creatine has been shown to be neuroprotective in aging, neurodegenerative
conditions and brain injury. As a common molecular background, oxidative stress
and disturbed cellular energy homeostasis are key aspects in these conditions.
Moreover, in a recent report we could demonstrate a life-enhancing and
health-promoting potential of creatine in rodents, mainly due to its
neuroprotective action. In order to investigate the underlying pharmacology
mediating these mainly neuroprotective properties of creatine, cultured primary
embryonal hippocampal and cortical cells were challenged with glutamate or
H(2)O(2). In good agreement with our in vivo data, creatine mediated a direct
effect on the bioenergetic balance, leading to an enhanced cellular energy
charge, thereby acting as a neuroprotectant. Moreover, creatine effectively
antagonized the H(2)O(2)-induced ATP depletion and the excitotoxic response
towards glutamate, while not directly acting as an antioxidant. Additionally,
creatine mediated a direct inhibitory action on the NMDA receptor-mediated
calcium response, which initiates the excitotoxic cascade. Even excessive
concentrations of creatine had no neurotoxic effects, so that high-dose creatine
supplementation as a health-promoting agent in specific pathological situations
or as a primary prophylactic compound in risk populations seems feasible. In
conclusion, we were able to demonstrate that the protective potential of creatine
was primarily mediated by its impact on cellular energy metabolism and NMDA
receptor function, along with reduced glutamate spillover, oxidative stress and
subsequent excitotoxicity.
2. Amino Acids. 2011 May;40(5):1297-303.
Creatine in mouse models of neurodegeneration and aging.
Klopstock T(1), Elstner M, Bender A.
(1)Department of Neurology, Friedrich-Baur-Institute, University of Munich,
Ziemssenstrasse 1, Munich, Germany. [email protected]
The supplementation of creatine has shown a marked neuroprotective effect in
mouse models of neurodegenerative diseases (Parkinson's disease, Huntington's
disease, amyotrophic lateral sclerosis). This has been assigned to the known
bioenergetic, anti-apoptotic, anti-excitotoxic and anti-oxidant properties of
creatine. As aging and neurodegeneration share pathophysiological pathways, we
investigated the effect of oral creatine supplementation on aging in 162 aged
wild-type C57Bl/6J mice. The median healthy life span of creatine-fed mice was 9%
higher than in their control littermates, and they performed significantly better
in neurobehavioral tests. In brains of creatine-treated mice, there was a trend
toward a reduction of reactive oxygen species and significantly lower
accumulation of the "aging pigment" lipofuscin. Expression profiling showed an
upregulation of genes implicated in neuronal growth, neuroprotection, and
learning. These data showed that creatine improves health and longevity in mice.
Creatine may, therefore, be a promising food supplement to promote healthy human
aging. However, the strong neuroprotective effects in animal studies of creatine
have not been reproduced in human clinical trials (that have been conducted in
Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis).
The reasons for this translational gap are discussed. One obvious cause seems to
be that all previous human studies may have been underpowered. Large phase III
trials over long time periods are currently being conducted for Parkinson's
disease and Huntington's disease, and will possibly solve this issue.
3. Nutr Res. 2008 Mar;28(3):172-8.
Long-term creatine supplementation is safe in aged patients with Parkinson
disease.
Bender A(1), Samtleben W, Elstner M, Klopstock T.
(1)Department of Neurology, University of Munich-Klinikum Grosshadern, 81377 Munich,
Germany. [email protected]-muenchen.de
The food supplement creatine (Cr) is widely used by athletes as a natural
ergogenic compound. It has also been increasingly tested in neurodegenerative
diseases as a potential neuroprotective agent. Weight gain is the most common
side effect of Cr, but sporadic reports about the impairment of renal function
cause the most concerns with regard to its long-term use. Data from randomized
controlled trials on renal function in Cr-supplemented patients are scarce and
apply mainly to healthy young athletes. We systematically evaluated potential
side effects of Cr with a special focus on renal function in aged patients with
Parkinson disease as well as its current use in clinical medical research. Sixty
patients with Parkinson disease received either oral Cr (n = 40) or placebo (n =
20) with a dose of 4 g/d for a period of 2 years. Possible side effects as
indicated by a broad range of laboratory blood and urine tests were evaluated
during 6 follow-up study visits. Overall, Cr was well tolerated. Main side
effects were gastrointestinal complaints. Although serum creatinine levels
increased in Cr patients because of the degradation of Cr, all other markers of
tubular or glomerular renal function, especially cystatin C, remained normal,
indicating unaltered kidney function. The data in this trial provide a thorough
analysis and give a detailed overview about the safety profile of Cr in older age
patients.
4. Am J Physiol Regul Integr Comp Physiol. 2007 Apr;292(4):R1745-50.
Cerebral energetic effects of creatine supplementation in humans.
Pan JW(1), Takahashi K.
(1)Department of Neurosurgery, Yale University School of Medicine, New Haven, CT
06520, USA.
There has been considerable interest in the use of creatine (Cr) supplementation
to treat neurological disorders. However, in contrast to muscle physiology, there
are relatively few studies of creatine supplementation in the brain. In this
report, we use high-field MR (31)P and (1)H spectroscopic imaging of human brain
with a 7-day protocol of oral Cr supplementation to examine its effects on
cerebral energetics (phosphocreatine, PCr; ATP) and mitochondrial metabolism
(N-acetyl aspartate, NAA; and Cr). We find an increased ratio of PCr/ATP (day 0,
0.80 +/- 0.10; day 7, 0.85 +/- 09), with this change largely due to decreased
ATP, from 2.7 +/- 0.3 mM to 2.5 +/- 0.3 mM. The ratio of NAA/Cr also decreased
(day 0, 1.32 +/- 0.17; day 7 1.18 +/- 0.13), primarily from increased Cr (9.6 +/-
1.9 to 10.1 +/- 2.0 mM). The Cr-induced changes significantly correlated with the
basal state, with the fractional increase in PCr/ATP negatively correlating with
the basal PCr/ATP value (R = -0.74, P < 0.001). As NAA is a measure of
mitochondrial function, there was also a significant negative correlation between
basal NAA concentrations with the fractional change in PCr and ATP. Thus healthy
human brain energetics is malleable and shifts with 7 days of Cr supplementation,
with the regions of initially low PCr showing the largest increments in PCr.
Overall, Cr supplementation appears to improve high-energy phosphate turnover in
healthy brain and can result in either a decrease or an increase in high-energy
phosphate concentrations.
5. J Neurosci. 2004 Jun 30;24(26):5909-12.
Prophylactic creatine administration mediates neuroprotection in cerebral
ischemia in mice.
Zhu S(1), Li M, Figueroa BE, Liu A, Stavrovskaya IG, Pasinelli P, Beal MF, Brown
RH Jr, Kristal BS, Ferrante RJ, Friedlander RM.
(1)Neuroapoptosis Laboratory, Department of Neurosurgery, Brigham and Women's
Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Creatine mediates remarkable neuroprotection in experimental models of
amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, and
traumatic brain injury. Because caspase-mediated pathways are shared functional
mechanistic components in these diseases, as well as in ischemia, we evaluated
the effect of creatine supplementation on an experimental stroke model. Oral
creatine administration resulted in a remarkable reduction in ischemic brain
infarction and neuroprotection after cerebral ischemia in mice. Postischemic
caspase-3 activation and cytochrome c release were significantly reduced in
creatine-treated mice. Creatine administration buffered ischemia-mediated
cerebral ATP depletion. These data provide the first direct correlation between
the preservation of bioenergetic cellular status and the inhibition of activation
of caspase cell-death pathways in vivo. An alternative explanation to our
findings is that creatine is neuroprotective through other mechanisms that are
independent of mitochondrial cell-death pathways, and therefore postischemic ATP
preservation is the result of tissue sparing. Given its safety record, creatine
might be considered as a novel therapeutic agent for inhibition of ischemic brain
injury in humans. Prophylactic creatine supplementation, similar to what is
recommended for an agent such as aspirin, may be considered for patients in high
stroke-risk categories.
Int J Dev Neurosci. 2004 Apr;22(2):95-101.
Tryptophan reduces creatine kinase activity in the brain cortex of rats.
Cornelio AR(1), Rodrigues V Jr, de Souza Wyse AT, Dutra-Filho CS, Wajner M,
Wannmacher CM.
(1)Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade
Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2600, CEP 90.035-003, Porto
Alegre, RS, Brazil.
Hypertryptophanemia is a rare inherited metabolic disorder probably caused by a
blockage in the conversion of tryptophan to kynurenine, resulting in the
accumulation of tryptophan and some of its metabolites in plasma and tissues of
affected patients. The patients present mild-to-moderate mental retardation with
exaggerated affective responses, periodic mood swings, and apparent hypersexual
behavior. Creatine kinase plays a key role in energy metabolism of tissues with
intermittently high and fluctuating energy requirements, such as nervous tissue.
The main objective of the present study was to investigate the effect of acute
administration of tryptophan on creatine kinase activity in brain cortex of
Wistar rats. We also studied the in vitro effect of this amino acid on creatine
kinase activity in the brain cortex of non-treated rats. The results indicated
that tryptophan inhibits creatine kinase in vitro and in vivo. We also observed
that the in vitro inhibition was fully prevented but not reversed by
pre-incubation with reduced glutathione, suggesting that the inhibitory effect of
tryptophan on CK activity is possibly mediated by oxidation of essential thiol
groups of the enzyme and/or long-lasting adduct formation. Considering the
importance of creatine kinase for the maintenance of energy homeostasis in the
brain, it is conceivable that an inhibition of this enzyme activity in the brain
may be one of the mechanisms by which tryptophan might be neurotoxic.
Curr Pharm Biotechnol. 2009 Nov;10(7):683-90.
Clinical applications of creatine supplementation on paediatrics.
Evangeliou A(1), Vasilaki K, Karagianni P, Nikolaidis N.
(1)4th Department of Pediatrics, Aristotle University, Thessaloniki, Greece.
[email protected]
Creatine plays a central role in energy metabolism and is synthesized in the
liver, kidney and pancreas. In healthy patients, it is transported via the blood
stream to the muscles, heart and brain with high and fluctuating energy demands
by the molecule creatine transporter. Creatine, although naturally synthesized in
the human body, can be ingested in the form of supplements and is commonly used
by athletes. The purpose of this review was to assess the clinical applications
of creatine supplementation on paediatrics. Creatine metabolism disorders have so
far been described at the level of two synthetic steps, guanidinoacetate
N-methyltransferase (GAMT) and arginine: glycine amidinotransferase (AGAT), and
at the level of the creatine transporter 1(CrT1). GAMT and AGAT deficiency
respond positively to substitutive treatment with creatine monohydrate whereas in
CrT1 defect, it is not able to replenish creatine in the brain with oral creatine
supplementation. There are also data concerning the short and long-term
therapeutic benefit of creatine supplementation in children and adults with
gyrate atrophy (a result of the inborn error of metabolism with ornithine delta-
aminotransferase activity), muscular dystrophy (facioscapulohumeral dystrophy,
Becker dystrophy, Duchenne dystrophy and sarcoglycan deficient limb girdle
muscular dystrophy), McArdle's disease, Huntington's disease and
mitochondria-related diseases. Hypoxia and energy related brain pathologies
(brain trauma, cerebral ischemia, prematurity) might benefit from Cr
supplementation. This review covers also the basics of creatine metabolism and
proposed mechanisms of action.
Neuroradiology. 2007 Feb;49(2):121-7.
Utilization of glutamate/creatine ratios for proton spectroscopic diagnosis of
meningiomas.
Hazany S(1), Hesselink JR, Healy JF, Imbesi SG.
(1)School of Medicine, University of California, San Diego, CA, USA.
INTRODUCTION: Our purpose was to determine the potential of metabolites other
than alanine to diagnose intracranial meningiomas on proton magnetic resonance
spectroscopy (MRS).
METHODS: Using a 1.5-T MR system the lesions were initially identified on FLAIR,
and T1- and T2-weighted images. Employing standard point-resolved spectroscopy
(PRESS) for single voxel proton MRS (TR 1500 ms, TE 30 ms, 128 acquisitions,
voxel size 2 x 2 x 2 cm, acquisition time 3.12 min), MR spectra were obtained
from 5 patients with meningiomas, from 20 with other intracranial lesions, and
from 4 normal controls. Peak heights of nine resonances, including lipid,
lactate, alanine, NAA (N-acetylaspartate), beta/gamma-Glx (glutamate +
glutamine), creatine, choline, myo-inositol, and alpha-Glx/glutathione, were
measured in all spectra. The relative quantity of each metabolite was measured as
the ratio of its peak height to the peak height of creatine.
RESULTS: Relative quantities of alpha-Glx/glutathione, beta/gamma-Glx, and total
Glx/glutathione were significantly elevated in meningiomas compared to the 20
other intracranial lesions and the normal control brains. Alanine was found in
four of five meningiomas, but lactate partially masked the alanine in three
meningiomas. None of the other lesions or control brains showed an alanine peak.
The one meningioma with no alanine and the three others with lactate had elevated
Glx.
CONCLUSION: While alanine is a relatively unique marker for meningioma, our
results support the hypothesis that the combination of glutamate/creatine ratios
and alanine on proton MRS is more specific and reliable for the diagnosis of
meningiomas than alanine alone.
J Neurotrauma. 2009 Oct;26(10):1635-43.
Neurometabolite concentrations in gray and white matter in mild traumatic brain
injury: an 1H-magnetic resonance spectroscopy study.
Gasparovic C(1), Yeo R, Mannell M, Ling J, Elgie R, Phillips J, Doezema D, Mayer
AR.
(1)The Mind Research Network, Albuquerque, New Mexico 7131, [email protected]
Single-voxel proton magnetic resonance imaging ((1)H-MRS) and proton MR
spectroscopic imaging ((1)H-MRSI) were used to compare brain metabolite levels in
semi-acute mild traumatic brain injury (mTBI) patients (n = 10) and matched
healthy controls (n = 9). The (1)H-MRS voxel was positioned in the splenium, a
region known to be susceptible to axonal injury in TBI, and a single (1)H-MRSI
slice was positioned above the lateral ventricles. To increase sensitivity to the
glutamate (Glu) and the combined glutamate-glutamine (Glx) signal, an inter-pulse
echo time shown to emphasize the major Glu signals was used along with an
analysis method that reduces partial volume errors by using water as a
concentration standard. Our preliminary findings indicate significantly lower
levels of gray matter Glx and higher levels of white matter
creatine-phosphocreatine (Cr) in mTBI subjects relative to healthy controls.
Furthermore, Cr levels were predictive of executive function and emotional
distress in the combined groups. These results suggest that perturbations in Cr,
a critical component of the brain's energy metabolism, and Glu, the brain's major
neurotransmitter, may occur following mTBI. Moreover, the different pattern of
results for gray and white matter suggests tissue-specific metabolic responses to
mTBI.